v3.26.1
Statement of Changes in Shareholder's Deficit - USD ($)
Preferred Stock [Member]
Titan Pharmaceuticals Inc [Member]
Common Stock [Member]
Titan Pharmaceuticals Inc [Member]
Common Stock [Member]
Common Stock [Member]
TALENTEC SDN. BHD. [Member]
Additional Paid-in Capital [Member]
Titan Pharmaceuticals Inc [Member]
Additional Paid-in Capital [Member]
TALENTEC SDN. BHD. [Member]
Retained Earnings [Member]
Titan Pharmaceuticals Inc [Member]
Retained Earnings [Member]
Retained Earnings [Member]
TALENTEC SDN. BHD. [Member]
AOCI Attributable to Parent [Member]
Titan Pharmaceuticals Inc [Member]
AOCI Attributable to Parent [Member]
TALENTEC SDN. BHD. [Member]
Titan Pharmaceuticals Inc [Member]
Total
TALENTEC SDN. BHD. [Member]
Balance at Jul. 31, 2023       $ 191,482       $ (412,345)   $ (21,619)     $ (242,482)
Balance, shares at Jul. 31, 2023       500,000                    
Net income (loss)             153,227       153,227
Shares issued       $ 17,135   782,865           800,000
Shares issued, shares       80,000                    
Foreign currency translation adjustment               (30,932)     (30,932)
Balance at Jul. 31, 2024     $ 208,617   782,865   $ (3,947) (259,118)   (52,551)   $ (3,947) 679,813
Balance, shares at Jul. 31, 2024     1 580,000                    
Balance at Dec. 31, 2023 $ 1,000 $ 1,000     $ 398,470,000   $ (391,830,000)       $ 6,642,000    
Balance, shares at Dec. 31, 2023 950 782                        
Net income (loss)       (4,706,000)       (4,706,000)    
Issuance of common stock upon conversion of note payable     504,000         504,000    
Issuance of common stock upon conversion of note payable, shares   54                        
Fractional shares issued due to reverse stock split                
Fractional shares issued due to reverse stock split, shares   78                        
Balance at Dec. 31, 2024 $ 1,000 $ 1,000     398,974,000   (396,536,000)       2,440,000    
Balance, shares at Dec. 31, 2024 950 914                        
Balance at Jul. 10, 2024                      
Balance, shares at Jul. 10, 2024                          
Net income (loss)             (3,947)         (3,947)  
Shares issued                      
Shares issued, shares     1                      
Balance at Jul. 31, 2024     $ 208,617   782,865   (3,947) (259,118)   (52,551)   (3,947) 679,813
Balance, shares at Jul. 31, 2024     1 580,000                    
Net income (loss)         (163,173) 209,911     (163,173) 209,911
Foreign currency translation adjustment               64,567     64,567
Balance at Jul. 31, 2025     $ 208,617   $ 782,865   $ (167,120) $ (49,207)   $ 12,016   $ (167,120) $ 954,291
Balance, shares at Jul. 31, 2025     1 580,000                    
Balance at Dec. 31, 2024 $ 1,000 $ 1,000     398,974,000   (396,536,000)       2,440,000    
Balance, shares at Dec. 31, 2024 950 914                        
Net income (loss)       (2,485,000)       (2,485,000)    
Issuance of common stock upon conversion of note payable, shares   483                        
Shares issued       1,600,000           1,600,000    
Shares issued, shares 160                          
Issuance of common stock upon conversion of preferred stock                
Issuance of common stock upon conversion of preferred stock, shares (240)                          
Recapitalization upon merger with Black Titan Corporation $ (1,000) $ (1,000)     2,000            
Recapitalization upon merger with Black Titan, shares (870) (1,396)                        
Balance at Dec. 31, 2025     $ 400,576,000   $ (399,021,000)       $ 1,555,000    
Balance, shares at Dec. 31, 2025 1